Drug Discovery & Development - October 20, 2010
LITTLE ROCK, Ark. (AP) - A federal jury has sided with Wyeth Pharmaceuticals in the latest lawsuit that accused the drugmaker of not disclosing a link between its hormone replacement therapy and a higher risk of breast cancer.
A Little Rock jury deliberated briefly Tuesday before siding with Wyeth, which argued that it adequately warned doctors and patients of the risks associated with its Prempro and Premarin drugs.
Margaret Wilson and her husband, Billy Wilson, sued the drugmaker after she developed breast cancer after taking Prempro for 4½ years. The suit was one of thousands pending nationwide over the hormone replacement therapy.
Pfizer Inc. bought Wyeth for $68 billion in 2009.
Date: October 19, 2010
Source: Associated Press
A Little Rock jury deliberated briefly Tuesday before siding with Wyeth, which argued that it adequately warned doctors and patients of the risks associated with its Prempro and Premarin drugs.
Margaret Wilson and her husband, Billy Wilson, sued the drugmaker after she developed breast cancer after taking Prempro for 4½ years. The suit was one of thousands pending nationwide over the hormone replacement therapy.
Pfizer Inc. bought Wyeth for $68 billion in 2009.
Date: October 19, 2010
Source: Associated Press
No hay comentarios:
Publicar un comentario